Joseph Picoraro1, Gabriel Winberry, Corey A Siegel, Wael El-Matary, Jonathan Moses, Andrew Grossman, K T Park. 1. *Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Columbia University Medical Center, New York, New York; †Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; ‡Inflammatory Bowel Disease Center, Section of Gastroenterology and Hepatology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire; §Department of Pediatrics, Section of Gastroenterology, Hepatology and Nutrition, University of Manitoba, Winnipeg, Manitoba, Canada; ‖Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, UH Rainbow Babies and Children's Hospital, Cleveland, Ohio; ¶Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania; and **Department of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Stanford Children's Health, Palo Alto, California.
Abstract
BACKGROUND: Premedications are commonly given to patients with inflammatory bowel disease before intravenous infliximab administration. We aimed to (1) describe practice variability; and (2) determine clinician rationale for premedicating patients with inflammatory bowel disease before infliximab administration. METHODS: We developed a cross-sectional electronic survey after comprehensive literature review to assess practice variability and clinician rationale for premedication use before infliximab. An optional postsurvey quiz assessed clinicians' understanding of the available literature. The survey was distributed through members-only NASPGHAN and Crohn's and Colitis Foundation of America (CCFA) listservs and American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG) web-based discussion boards. RESULTS: Three hundred seventy-nine unique respondents with a 93.3% survey completion rate comprised 331 (87%) and 45 (12%) pediatric and adult gastroenterologists. Among numerous options for premedications, acetaminophen (66%) and diphenhydramine (64%) were most often given before each infliximab infusion. Only 20% did not routinely use premedications. There was heterogeneity of premedication use between gastroenterologists within the same clinical practice. Of 328 (87%) respondents who completed the knowledge assessment quiz, only 18% identified the association of diphenhydramine use with increased reaction. CONCLUSIONS: There is high interpractice and intrapractice variability for premedication use before infliximab administration. Clinician rationale for premedicating patients seems to be driven by individual preference or group practice habit. Improved knowledge of the evidence may assist in decreasing overuse of premedications, particularly diphenhydramine.
BACKGROUND: Premedications are commonly given to patients with inflammatory bowel disease before intravenous infliximab administration. We aimed to (1) describe practice variability; and (2) determine clinician rationale for premedicating patients with inflammatory bowel disease before infliximab administration. METHODS: We developed a cross-sectional electronic survey after comprehensive literature review to assess practice variability and clinician rationale for premedication use before infliximab. An optional postsurvey quiz assessed clinicians' understanding of the available literature. The survey was distributed through members-only NASPGHAN and Crohn's and Colitis Foundation of America (CCFA) listservs and American Gastroenterological Association (AGA) and American College of Gastroenterology (ACG) web-based discussion boards. RESULTS: Three hundred seventy-nine unique respondents with a 93.3% survey completion rate comprised 331 (87%) and 45 (12%) pediatric and adult gastroenterologists. Among numerous options for premedications, acetaminophen (66%) and diphenhydramine (64%) were most often given before each infliximab infusion. Only 20% did not routinely use premedications. There was heterogeneity of premedication use between gastroenterologists within the same clinical practice. Of 328 (87%) respondents who completed the knowledge assessment quiz, only 18% identified the association of diphenhydramine use with increased reaction. CONCLUSIONS: There is high interpractice and intrapractice variability for premedication use before infliximab administration. Clinician rationale for premedicating patients seems to be driven by individual preference or group practice habit. Improved knowledge of the evidence may assist in decreasing overuse of premedications, particularly diphenhydramine.
Authors: Richard J Farrell; Mazen Alsahli; Yoon-Tae Jeen; Kenneth R Falchuk; Mark A Peppercorn; Pierre Michetti Journal: Gastroenterology Date: 2003-04 Impact factor: 22.682
Authors: Paul Rutgeerts; William J Sandborn; Brian G Feagan; Walter Reinisch; Allan Olson; Jewel Johanns; Suzanne Travers; Daniel Rachmilewitz; Stephen B Hanauer; Gary R Lichtenstein; Willem J S de Villiers; Daniel Present; Bruce E Sands; Jean Frédéric Colombel Journal: N Engl J Med Date: 2005-12-08 Impact factor: 91.245
Authors: C Steenholdt; M Svenson; K Bendtzen; O Ø Thomsen; J Brynskov; M A Ainsworth Journal: Aliment Pharmacol Ther Date: 2011-05-03 Impact factor: 8.171
Authors: Filip Baert; Maja Noman; Severine Vermeire; Gert Van Assche; Geert D' Haens; An Carbonez; Paul Rutgeerts Journal: N Engl J Med Date: 2003-02-13 Impact factor: 91.245
Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts Journal: Lancet Date: 2002-05-04 Impact factor: 79.321
Authors: Jeremy Adler; Kelly C Sandberg; Benjamin H Shpeen; Sally J Eder; Muhammad Dhanani; Sarah J Clark; Gary L Freed Journal: J Pediatr Gastroenterol Nutr Date: 2013-07 Impact factor: 2.839
Authors: Elaine Barfield; Robbyn Sockolow; Edward Hoffenberg; Shehzad Saeed; Sandra Kim; Leah Siebold; Joseph Picoraro; Jonathan Moses; Dana Dykes; Andrew Grossman; Ghassan Wahbeh; K T Park Journal: J Pediatr Gastroenterol Nutr Date: 2018-04 Impact factor: 2.839
Authors: Elsa A van Wassenaer; Floris A E de Voogd; Rick R van Rijn; Johanna H van Der Lee; Merit M Tabbers; Faridi S van Etten-Jamaludin; Krisztina B Gecse; Angelika Kindermann; Tim G J De Meij; Geert R D'haens; Marc A Benninga; Bart G P Koot Journal: J Crohns Colitis Date: 2019-12-10 Impact factor: 9.071